Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate

Abstract

In a recent randomized, double-blind, placebo-controlled trial, we established a robust efficacy (Cohen’s d = 2.17) of osmotic release oral system-methylphenidate (OROS-methylphenidate) delivered 72 mg daily for 5 weeks versus placebo on attention deficit hyperactivity disorder (ADHD) symptoms, global severity and global functioning in 30 adult male prison… (More)
DOI: 10.1007/s00406-012-0317-8

Topics

8 Figures and Tables